# A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

> **NCT02729896** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 36 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Atezolizumab [TECENTRIQ]
- **DRUG:** Obinutuzumab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02729896
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-09
- **Primary completion:** 2018-09-03
- **Final completion:** 2019-10-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02729896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02729896, "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02729896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*